Bone mineral density in users of two kinds of once-a-month combined injectable contraceptives

Contraception

Volumn 74, Issue 3, 2006, Pages 259-263

  Bahamondes, Luis ^a   Juliato, Cássia Teatin ^a   Villarreal, Marina ^a   Sobreira Lima, Bruno ^a   Simões, José A ^a   dos Santos Fernandes, Arlete M ^a  

^a Department of Obstetrics and Gynecology School of Medicine Universida de Estadual de Campinas   (Brazil)

Author keywords

Bone mineral density; Combined injectable contraceptives; Contraception

Indexed keywords

COPPER INTRAUTERINE DEVICE; ESTRADIOL CIPIONATE; ESTRADIOL VALERATE; INJECTABLE CONTRACEPTIVE AGENT; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE ENANTATE;

ADULT; ARTICLE; BODY MASS; BONE DENSITY; CLINICAL ARTICLE; CONTRACEPTION; CONTROLLED STUDY; DESCRIPTIVE RESEARCH; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FOREARM; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; MAJOR CLINICAL STUDY; MATERNAL AGE; ULNA;

ABSORPTIOMETRY, PHOTON; ADULT; BODY MASS INDEX; BONE DENSITY; CONTRACEPTIVE AGENTS, FEMALE; CROSS-SECTIONAL STUDIES; DENSITOMETRY, X-RAY; ESTRADIOL; FEMALE; HUMANS; INJECTIONS; MEDROXYPROGESTERONE 17-ACETATE; MEDROXYPROGESTERONE ACETATE; NORETHINDRONE; RADIUS; ULNA;

EID: 33746782594     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2006.03.019     Document Type: Article

References (36)

1. World Health Organization. Medical eligibility criteria for contraceptive use. 3rd ed. (2004), WHO, Geneva
2. World Health Organization. WHO statement on hormonal contraception and bone health (2005), WHO, Geneva
3. Riggs III B.L., and Melton J.L. Involutional osteoporosis. N Engl J Med 314 (1986) 1676-1686
4. Recker R.R., Davies K.M., Hinders S.M., Heaney R.P., Stegman M.R., and Kimmel D.B. Bone gain in young adult women. JAMA 17 (1992) 2403-2408
5. United States Food and Drug Administration. Black box warning on Depo-Provera contraceptive injection. November 17, 2004. http://www.fda.bbs.topics/ANSWERS/2004/ANS)1325.html
6. Duff G. Updated prescribing advice on the effect of Depo-Provera contraception on bones. HSS (MD) 39-2004, November, 18, 2004. http://www.medicines.mhra.gov.uk/ourwork/monitorsafequalmed/safetymessages/Depot-Provera_letterhealthprofs_181104.pdf [November 19, 2004]
7. Gbolade B., Ellis S., Murby B., Randall S., and Kirkman R. Bone density in long-term users of depot medroxyprogesterone acetate. BJOG 105 (1998) 790-794
8. Bahamondes L., Trevisan M., Andrade L., et al. The effect upon the human vaginal histology of the long-term use of the injectable contraceptive Depo-Provera. Contraception 62 (2000) 23-27
9. Kaunitz A.M. Depo-Provera's black box: time to reconsider?. Contraception 72 (2005) 165-167
10. Bahamondes L., Perrotti M., Castro S., Faúndes D., Petta C., and Bedone A. Forearm bone density in users of Depo-Provera as a contraceptive method. Fertil Steril 71 (1999) 849-852
11. Newton J.R. A review of "once-a-month" combined injectable contraceptives. J Obstet Gynaecol 14 Suppl 1 (1994) S1-S34
12. Kaunitz A.M. Injectable contraception. New and existing options. Obstet Gynecol Clin North Am 27 (2000) 741-780
13. Upadhyay UD, New contraceptive choices. Population Reports, M. Series, No. 19. Baltimore: Johns Hopkins Bloomberg School of Public Health, The INFO Project. April, 2005.
14. Hall P., Bahamondes L., Diaz J., and Petta C. Introductory study of the once-a-month, injectable contraceptive Cyclofem in Brazil, Chile, Colombia, and Peru. Contraception 56 (1997) 353-359
15. Bahamondes L., Lavin P., Ojeda G., et al. Return of fertility after discontinuation of the once-a-month injectable contraceptive Cyclofem. Contraception 55 (1997) 307-310
16. Castelo-Branco C., Vicente J.J., Pons F., Martinez de Osaba M.J., Casals E., and Vanrell J.A. Bone mineral density in young, hypothalamic oligoamenorrheic women treated with oral contraceptives. J Reprod Med 46 (2001) 875-879
17. Rickenlund A., Carlstrom K., Ekblom B., Brismar T.B., Von S.B., and Hirschberg A.L. Effects of oral contraceptives on body composition and physical performance in female athletes. J Clin Endocrinol Metab 89 (2004) 4364-4370
18. Polatti F., Perotti F., Filippa N., Gallina D., and Nappi R.E. Bone mass and long-term monophasic oral contraceptive treatment in young women. Contraception 51 (1995) 221-224
19. Perrotti M., Bahamondes L., Petta C., and Castro S. Forearm bone density in long-term users of oral combined contraceptives and depot medroxyprogesterone acetate. Fertil Steril 76 (2001) 469-473
20. Nappi C., Di Spiezio Sardo A., Acunzo G., et al. Effects of a low-dose and ultra-low-dose combined oral contraceptive use on bone turnover and bone mineral density in young fertile women: a prospective controlled randomized study. Contraception 67 (2003) 355-359
21. Barad D., Kooperberg C., Wactawski-Wende J., Liu J., Hendrix S., and Watts N.B. Prior oral contraception and postmenopausal fracture: a Women's Health Initiative observational cohort study. Fertil Steril 84 (2005) 374-383
22. Marshall D., Johnell O., and Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312 (1996) 1254-1259
23. von Kesseru E., Etchepareborda J.J., Wikinski R., and Beier S. Premenopause contraception with monthly injectable Mesigyna with special emphasis on serum lipid and bone density patterns. Contraception 61 (2000) 317-322
24. Oriowo M.A., Landgren B.M., Stenstrom B., and Diczfalusy E. A comparison of the pharmacokinetic properties of three estradiol esters. Contraception 21 (1980) 415-424
25. Aedo A.R., Landgren B.M., Johannisson E., and Diczfalusy E. Pharmacokinetic and pharmacodynamic investigations with monthly injectable contraceptive preparations. Contraception 31 (1985) 453-469
26. Bassol S., Hernandez C., Nava M.P., Trujillo A.M., and Luz de la Cruz D. A comparative study on the return to ovulation following chronic use of once-a-month injectable contraceptives. Contraception 51 (1995) 307-311
27. Sang G.W. Pharmacodynamic effects of once-a-month combined injectable contraceptives. Contraception 49 (1994) 361-385
28. Massai R., Makarainen L., Kuukankorpi A., Klipping C., Duijkers I., and Dieben T. The combined contraceptive vaginal ring and bone mineral density in healthy pre-menopausal women. Hum Reprod 20 (2005) 2764-2768
29. World Health Organization. Assessment of fracture risk and its application to screening for post-menopausal osteoporosis: report of a WHO study group (1994), WHO, Geneva [technical report series 843]
30. Doren M., Nilsson J.A., and Johnell O. Effects of specific post-menopausal hormone therapies on bone mineral density in post-menopausal women: a meta-analysis. Hum Reprod 18 (2003) 1737-1746
31. Lindsay R., Tohme J., and Kanders B. The effect of oral contraceptive use on vertebral bone mass in pre- and post-menopausal women. Contraception 34 (1986) 333-340
32. Lloyd T., Petit M.A., Lin H.M., and Beck T.J. Lifestyle factors and the development of bone mass and bone strength in young women. J Pediatr 144 (2004) 776-782
33. Cromer B.A., Blair J.M., Mahan J.D., Zibners L., and Naumovski Z. A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo Provera), levonorgestrel (Norplant), or oral contraceptives. J Pediatr 129 (1996) 671-676
34. Kleerekoper M., Brienza R.S., Schultz L.R., Johnson C.C., and Henry Ford Hospital Osteoporosis Cooperative Research Group. Oral contraceptive use may protect against low bone mass. Arch Intern Med 151 (1991) 1971-1976
35. Cooper C., Hannaford P., Croft P., and Kay C.R. Oral contraceptive pill use and fractures in women: a prospective study. Bone 14 (1993) 41-45
36. Michaelsson K., Baron J.A., Farahmand B.Y., Persson I., and Ljunghall S. Oral contraceptive use and risk of hip fracture: a case-control study. Lancet 353 (1999) 1481-1484